Rivastigmine as a Modulator of the Neuronal Glutamate Transporter rEAAC1 mRNA Expression

Andin, Josefine,1979-Linköpings universitet,Geriatrik,Hälsouniversitetet (författare)

Alzheimer’s disease is a neurodegenerative disorder that affects the cholinergic, glutamatergic and monoaminergic systems in the neocortex and hippocampus. Today, the major pharmacological treatment involves the use of acetylcholinesterase inhibitors (AChEIs). In this study, an in situ hybridisation technique (using digoxigenin-labelled cRNA probes) was used to elucidate changes in mRNA expression of the neuronal glutamate transporter, rat excitatory amino carrier 1 (rEAAC1), after treatment with the AChEI rivastigmine. Compared with saline-treated rats, the rats subchronically (3 days) and chronically (21 days), but not acutely, treated with rivastigmine showed a significant increase in rEAAC1 mRNA expression in the hippocampal areas cornu anterior 1 (CA1), CA2, CA3 and dentate gyrus (p < 0.01), but not in the cortical areas. These results provide the first evidence that the glutamatergic system is modulated following acetylcholinesterase inhibition by rivastigmine, a finding, which is likely to be of importance for the clinical effects.

Enz, AlbertNeuroscience Research, The Novartis Institutes for BioMedical Research, Basel, Switzerland (författare)
Gentsch, ConradNeuroscience Research, The Novartis Institutes for BioMedical Research, Basel, Switzerland (författare)
Marcusson, Jan,1958-Linköpings universitet,Geriatrik,Hälsouniversitetet(Swepub:liu)janma25 (författare)
Linköpings universitetGeriatrik (creator_code:org_t)

Ingår i:Dementia and Geriatric Cognitive Disorders: S. Karger AG19:1, s. 18-231420-80081421-9824

Av författaren/redakt...: Andin, Josefine, ...; Enz, Albert; Gentsch, Conrad; Marcusson, Jan, ...

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.